GlassScriptPhysician profile
Catherine Jimenez
NPI 1710446661
$1,785.44
in general payments reported to CMS, 2019-2025
16 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.29 · 2023: $479 · 2024: $589 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $412.86 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $394.11 | 2022-2025 | |
| Astellas Pharma US INC | $264.74 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $213.40 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $99.50 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $79.88 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $61.51 | 2023-2025 | |
| Organogenesis INC. | $47.20 | 2023-2024 | Puraply |
| Amgen INC. | $40.52 | 2024-2025 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $38.83 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $36.74 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Otsuka America Pharmaceutical, INC. | $26.24 | 2025 | Rexulti |
| Dexcom, INC. | $23.23 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $16.83 | 2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.40 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.